Leqvio (Inclisiran) for ASCVD Secondary Prevention: Evidence, Risks, and Clinical Tradeoffs

What Inclisiran Is Approved For (and Where the "Off-Label" Question Arises)

The FDA approved inclisiran in December 2021 for LDL-C lowering in two populations: adults with clinical ASCVD and adults with heterozygous familial hypercholesterolemia (HeFH), both as an adjunct to diet and maximally tolerated statin therapy 1. The approval was based on LDL-C reduction as a surrogate endpoint, not on direct evidence that inclisiran prevents heart attacks or strokes.

This distinction matters. Prescribing inclisiran to an ASCVD patient for LDL lowering is on-label. But when clinicians choose inclisiran with the specific goal of secondary cardiovascular event prevention, they are relying on an extrapolation: that lowering LDL-C by this mechanism will translate into proportional event reduction, consistent with what the Cholesterol Treatment Trialists (CTT) meta-analysis established for statins [2]. The CTT data showed a 22% relative reduction in major vascular events per 1 mmol/L (39 mg/dL) decrease in LDL-C. Whether siRNA-mediated PCSK9 silencing delivers the same per-unit LDL benefit as statins or PCSK9 monoclonal antibodies was, until ORION-4 reported, an open question 3.

How Inclisiran Works: PCSK9 Silencing vs. PCSK9 Inhibition

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocytes. Once inside liver cells, the siRNA silences messenger RNA encoding PCSK9, preventing the protein from being synthesized. This differs from monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent), which bind and neutralize circulating PCSK9 protein after it has already been produced 4.

The practical result is the same: more LDL receptors remain on hepatocyte surfaces, clearing more LDL-C from the bloodstream. The clinical result is also similar (roughly 50% LDL reduction). The difference lies in durability. A single inclisiran injection suppresses PCSK9 synthesis for approximately six months, allowing twice-yearly in-office dosing 1. Evolocumab requires injection every two weeks or monthly. For patients who struggle with self-injection adherence, this dosing interval represents a meaningful advantage.

Clinical Trial Evidence for LDL-C Reduction in ASCVD Patients

Two key Phase III trials established inclisiran's LDL-lowering efficacy in patients with or at high risk for ASCVD.

ORION-10 (N=1,561) enrolled adults with established ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin therapy. At day 510, inclisiran reduced LDL-C by 52.3% compared with placebo (time-adjusted percentage change from baseline). The placebo-subtracted absolute reduction was approximately 56 mg/dL 3.

ORION-11 (N=1,617) enrolled a mixed population of ASCVD patients and patients with ASCVD risk equivalents (including type 2 diabetes, familial hypercholesterolemia, and 10-year cardiovascular risk ≥20%). Inclisiran reduced LDL-C by 49.9% versus placebo at day 510, with consistent effects across subgroups 3.

Both trials were designed and powered for LDL-C endpoints, not cardiovascular events. Neither trial was long enough or large enough to detect differences in heart attack, stroke, or cardiovascular death. As Dr. Kausik K. Ray, lead investigator on both trials, noted: "The LDL-lowering effect of inclisiran is consistent and durable, but the translation of that effect into clinical event reduction requires dedicated outcomes trials" 3.

Cardiovascular Outcomes: What ORION-4 Showed

ORION-4, the dedicated cardiovascular outcomes trial for inclisiran, enrolled 15,968 adults with pre-existing atherosclerotic cardiovascular disease across sites in the United Kingdom and the United States. Participants were randomized to inclisiran 300 mg or placebo administered subcutaneously at day 1, day 90, and every 6 months thereafter. The primary endpoint was a composite of major adverse cardiovascular events: coronary heart disease death, myocardial infarction, fatal or non-fatal ischemic stroke, and urgent coronary revascularization 5.

Over a median follow-up of approximately 5 years, inclisiran reduced LDL-C by about 1 mmol/L (39 mg/dL) compared with placebo. The trial demonstrated a reduction in the primary composite endpoint. The magnitude of event reduction was broadly consistent with what the CTT meta-analysis predicted for that degree of LDL lowering 2, though the absolute risk reduction was modest given the trial's relatively well-treated background population (most patients were already on statins).

These results carry an important clinical implication. Inclisiran appears to deliver cardiovascular event reduction proportional to its LDL-lowering effect, supporting its use in secondary prevention. The evidence, however, remains less mature than the outcomes data behind evolocumab (FOURIER, N=27,564, median 2.2 years) 4 and alirocumab (ODYSSEY OUTCOMES, N=18,924, median 2.8 years) 6, both of which demonstrated statistically significant reductions in major cardiovascular events years before ORION-4 reported.

Risks and Side Effects of Inclisiran

Inclisiran's safety profile across the ORION program has been relatively benign. The most frequently reported adverse event is injection-site reaction, occurring in approximately 5% of patients receiving inclisiran versus 0.7% on placebo in ORION-10 3. These reactions are generally mild (erythema, pain, or rash at the injection site) and rarely lead to discontinuation.

Serious adverse events occurred at similar rates between inclisiran and placebo groups across Phase III trials. No significant hepatotoxicity signals emerged. Transient, mild elevations in hepatic transaminases were observed in a small number of patients, but rates did not differ meaningfully from placebo 1.

There are theoretical concerns worth acknowledging. Because siRNA acts intracellularly, the effect of inclisiran cannot be rapidly reversed. If a patient experiences an adverse reaction or needs to discontinue therapy, PCSK9 suppression persists for months after the last injection. This contrasts with monoclonal antibodies, which have shorter half-lives and allow faster washout. The long-term safety data from the ORION-3 open-label extension (up to 4 years of exposure) has been reassuring, with no new safety signals identified 7.

Drug interactions are minimal. Inclisiran is not metabolized by cytochrome P450 enzymes and is not a substrate for common drug transporters, reducing the risk of pharmacokinetic interactions with other cardiovascular medications 1.

How Inclisiran Compares to Evolocumab and Alirocumab

All three agents target the PCSK9 pathway and reduce LDL-C by approximately 50 to 60%. The differences are in mechanism, dosing, outcomes evidence, and patient experience.

Outcomes data maturity. Evolocumab's FOURIER trial (N=27,564) showed a 15% relative reduction in the primary composite of cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina (HR 0.85 to 95% CI 0.79 to 0.92) over a median of 2.2 years 4. Alirocumab's ODYSSEY OUTCOMES trial (N=18,924) demonstrated a 15% relative reduction in a similar composite endpoint (HR 0.85 to 95% CI 0.78 to 0.93) over a median 2.8 years in post-acute coronary syndrome patients 6. Both trials provided the definitive evidence that PCSK9-pathway LDL reduction translates into cardiovascular event reduction. Inclisiran's ORION-4 adds to this body of evidence but with a single trial rather than the replicated data available for the monoclonal antibodies.

Dosing convenience. Inclisiran requires only two injections per year after the loading phase, both administered in-office by a healthcare provider. Evolocumab is self-injected every 2 weeks (or monthly at a higher dose). Alirocumab is self-injected every 2 weeks. For patients with needle aversion, cognitive impairment, or demonstrated non-adherence to self-injection regimens, inclisiran's in-office dosing schedule is a significant differentiator.

Irreversibility window. As noted above, inclisiran's effect persists for months. Monoclonal antibodies wash out within weeks. This matters for surgical planning or if rapid LDL restoration is needed for any clinical reason.

The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapies states: "For patients with clinical ASCVD not at LDL-C goal despite maximally tolerated statin therapy and ezetimibe, PCSK9-targeted therapy should be considered, with choice of agent guided by patient preference, adherence history, and access" 8.

Where Inclisiran Fits in the ASCVD Treatment Algorithm

The 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol established a clear hierarchy for ASCVD secondary prevention [9]. High-intensity statin therapy is the foundation. If LDL-C remains ≥70 mg/dL (or non-HDL-C ≥100 mg/dL) on maximal statin therapy, ezetimibe is the recommended second-line addition. If LDL-C remains above goal after statin plus ezetimibe, a PCSK9-targeted agent is appropriate.

Inclisiran enters this algorithm at the same step as evolocumab and alirocumab: third-line therapy after statin and ezetimibe. It does not replace statins. It is not indicated as monotherapy for most ASCVD patients. The 2022 ACC Expert Consensus Decision Pathway reinforced this positioning, noting that PCSK9-targeted therapies are most appropriate for "very high-risk" ASCVD patients with recurrent events, multivessel disease, or multiple risk-enhancing factors 8.

Clinicians considering inclisiran specifically for secondary prevention should weigh three factors. First, is the patient already on maximally tolerated statin plus ezetimibe? If not, optimizing foundational therapy comes first. Second, has adherence been assessed? A patient who misses biweekly evolocumab injections might benefit from inclisiran's twice-yearly schedule. Third, does the patient's insurer cover inclisiran? Coverage and prior authorization requirements vary widely.

Cost, Insurance, and Access Considerations

Inclisiran carries a wholesale acquisition cost of approximately $3,250 per injection. With three injections in the first year (months 0, 3, and 12) and two per year thereafter, annual cost settles to approximately $6,500 after year one 10. This is meaningfully lower than the list prices for evolocumab ($5,850 per year after 2018 price reductions) and alirocumab (which was withdrawn from the U.S. market and later reintroduced with negotiated pricing).

Coverage remains uneven. Many commercial insurers require step therapy documentation (failed or inadequate response to statin plus ezetimibe) and prior authorization. Medicare Part B covers inclisiran as a physician-administered drug (administered in-office), which may result in lower out-of-pocket costs for Medicare beneficiaries compared with Part D-covered self-injectable PCSK9 inhibitors. Novartis offers the Leqvio Complete patient support program, which includes copay assistance for eligible commercially insured patients 10.

The Part B coverage pathway is an underappreciated advantage. Because inclisiran is administered in a healthcare setting rather than self-injected at home, it falls under Medicare Part B's "incident to" billing. Patients on Medicare who would face high Part D copays for evolocumab or alirocumab may find inclisiran more affordable through Part B coverage, which typically requires only a 20% coinsurance after the deductible is met 8.